Latest Breaking News On - Akero therapeutics - Page 15 : comparemela.com

HC Wainwright reissued their buy rating on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a research note released on Monday morning, Benzinga reports. They currently have a $50.00 price objective on the stock. HC Wainwright also issued estimates for Akero Therapeutics’ Q2 2024 earnings at ($0.82) EPS, Q3 2024 earnings at ($0.87) EPS, […]

New yorkUnited statesZurcher kantonalbank zurich cantonalbankCatriona yaleAndrew chengAkero therapeutics incSecurities exchange commissionAkero therapeutics company profileMirae asset global investments coTd asset management incYork state common retirement fundYork mellon corpAkero therapeuticsFree reportModerate buyGet free report